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RIASSUNTO IN ITALIAN O  
Il citomegalovirus umano (HCMV) è un virus che infetta la maggioranza degli adulti 
nel mondo. In pazienti sani, HCMV stimola una forte risposta immunitaria in grado di limitare 
e contenere il diffondersi dell’infezione, sebbene questo virus sia capace di restare latente 
nelle cellule infettate e di riattivarsi spontaneamente quando le condizioni sono più favorevoli. 
La forma acuta dell’infezione da HCMV è associata a particolari condizioni in cui il sistema 
immunitario è in qualche modo compromesso, ad esempio in pazienti che hanno ricevuto un 
trapianto d’organo, in pazienti affetti da sindrome da immunodeficienza acquisita (AIDS) o in 
feti che contraggono l’infezione congenita. HCMV possiede il più grande genoma tra gli 
herpesvirus e, nel tempo, la comunità scientifica sta cercando di esplorare il suo enorme 
potenziale di espressione. 
In questo studio ci siamo occupati del prodotto proteico dell’open reading frame (ORF) 
UL5, appartenente alla famiglia genica RL11 e ancora da caratterizzare. UL5 è presente 
soltanto nei citomegalovirus di umani e scimpanzé mentre è assente nei citomegalovirus che 
infettano altre specie e viene pertanto considerato un gene ‘privato’. La sequenza 
amminoacidica di UL5 è abbastanza conservata tra i diversi ceppi del citomegalovirus umano 
e tutte le differenze, benché minime, sono concentrate all’N-terminale. Predizioni in silico 
classificano pUL5 come una proteina di membrana di tipo Ib mancante di un peptide segnale e 
senza siti di N-glicosilazione, mentre sono predetti 7 siti di O-glicosilazione. In letteratura 
sono descritti tre mRNA di lunghezza simile contenenti UL5 insieme all’ORF precedente UL4. 
Per confermare questo ed escludere la presenza di altri trascritti contenenti UL5, abbiamo 
eseguito un Northern blot sull’RNA totale di cellule infettate da HCMV, estratto a vari tempi 
dopo l’infezione usando una sonda a DNA specifica per UL5. Il saggio ha evidenziato 
un’unica banda di circa 1.5 kb, escludendo la presenza di altri trascritti contenenti UL5. Allo 
scopo di studiare il prodotto proteico di UL5, abbiamo generato un virus ricombinante in cui 
una serie di tag ottimizzata (2StrepII-2FLAG) è stata aggiunta al C-terminale di pUL5 tramite 
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la mutagenesi a due step di un cromosoma batterico artificiale (BAC) contenente l’intero 
genoma del ceppo TR di HCMV. Per studiare il profilo di espressione di pUL5 è stato 
eseguito un immunoblot con un anticorpo anti-FLAG su lisati di fibroblasti infettati con il 
virus ricombinante, preparati a diversi tempi dopo l’infezione. Il Western blot ha rilevato la 
presenza di due specie di circa 24 e 15 kDa, espresse con cinetica late e early, rispettivamente. 
Poiché il peso molecolare atteso della proteina intera compresa di tag è 24.5 kDa, è probabile 
che questa corrisponda alla banda a peso più alto, suggerendo che non esistano forme 
glicosilate di pUL5. Per confermare questa teoria abbiamo effettuato un’analisi di 
deglicosilazione sia in trasfezione che in infezione e  non abbiamo rilevato alcuna differenza 
nell’altezza delle bande corrispondenti a pUL5. Per indagare sulla natura della banda a più 
basso peso molecolare abbiamo mutato un secondo ATG presente nella sequenza codificante 
di UL5 che potrebbe corrispondere ad un secondo codone d’inizio della traduzione. Abbiamo 
poi trasfettato delle cellule HEK293T con il plasmide di UL5 mutata ed eseguito un Western 
blot sui lisati, rilevando una forte riduzione nel segnale della banda a 15 kDa. Inoltre, abbiamo 
prodotto in E. coli una forma ricombinante di pUL5 mancante del tratto trans-membrana, 
l’abbiamo purificata e utilizzata per produrre un antisiero nei topi. Ripetendo gli esperimenti 
utilizzando il virus wild-type e l’antisiero di topo, abbiamo ottenuto gli stessi risultati, 
escludendo la possibilità di artefatti dovuti alla presenza dei tag. Esperimenti di microscopia 
confocale su fibroblasti infettati sia con il virus wild-type che con quello ricombinante e 
utilizzando sia l’antisiero di topo che l’anticorpo anti-FLAG hanno rilevato pUL5 in co-
localizzazione con marcatori del trans-Golgi network e delle vie secretorie, in un 
compartimento formato tipicamente durante l’infezione da HCMV e deputato 
all’assemblaggio dei nuovi virus. Allo scopo di verificare se pUL5 viene incorporata nei 
virioni maturi, abbiamo effettuato un Western blot su virioni purificati e non abbiamo 
riscontrato la presenza della proteina, che probabilmente viene espressa soltanto durante il 
ciclo di infezione ma non costituisce una componente strutturale del virus. Per cercare di 
capire quale possa essere il ruolo di pUL5 durante l’infezione, abbiamo creato un virus 
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ricombinante in cui l’intera ORF di UL5 è stata deleta mediante mutagenesi del BAC e 
abbiamo valutato la sua capacità di replicazione in fibroblasti umani. Il virus mutante knock-
out di UL5 si è rivelato ugualmente in grado di infettare fibroblasti ma con una cinetica di 
replicazione fortemente ridotta. Infine, abbiamo effettuato un esperimento di pull-down di 
pUL5 con il fine di identificare eventuali interattori. A questo scopo, abbiamo infettato dei 
fibroblasti umani con il virus ricombinante taggato e abbiamo immunoprecipitato pUL5 
utilizzando delle palline magnetiche rivestite di anticorpo anti-FLAG. L’analisi per 
spettrometria di massa dell’eluato ha portato all’identificazione della proteina cellulare 
IQGAP1 come uno degli interattori di pUL5. IQGAP1 è una proteina cellulare espressa in 
maniera ubiquitaria e coinvolta in molti meccanismi cellulari, tra cui il rimodellamento del 
citoscheletro, l’adesione cellulare e la regolazione del ciclo cellulare, oltre ad essere un noto 
bersaglio per i patogeni intracellulari. Questa interazione è stata ulteriormente confermata da 
immunoprecipitazioni reciproche in trasfezione, dando un ulteriore indizio su quale potrebbe 
essere il ruolo di pUL5 durante il ciclo di infezione di HCMV. 
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SUMMARY  
Human cytomegalovirus (HCMV) is a ubiquitous virus infecting the majority of adults 
worldwide. In healthy individuals, a strong immune response to HCMV is able to limit and 
contain the spread of the disease, although the virus is able to establish a lifelong lasting 
latency with recurrent and spontaneous reactivation. Acute disease is observed only in 
particular settings where the normal immune response of the patient is weak or compromised, 
such as in transplant or patients with Acquired Immuno-Deficiency Syndrome (AIDS) or in 
fetuses that acquire the infection congenitally. HCMV possesses the largest genome among 
herpesviruses and a lot of effort is being put on the study of the huge coding potential this 
virus displays in order to have a better understanding of the mechanisms behind its infection.  
In this work, we address the study of the protein product of UL5 open reading frame 
(ORF), belonging to the RL11 gene family and previously uncharacterized. UL5 is only 
present in human and chimpanzee cytomegaloviruses while is absent in cytomegaloviruses 
infecting other species, therefore is considered a ‘private’ gene. Among HCMV strains, UL5 
aminoacid sequence is relatively conserved and all minor differences are concentrated in the 
N-terminus. In silico predictions classify pUL5 as a type Ib membrane protein with no signal 
peptide and no N-linked glycosylations, while 7 O-glycosylation sites are predicted. Three 
different mRNAs with similar lengths including UL5 and the previous ORF UL4 have already 
been described in literature. In order to confirm these data and to exclude the presence of other 
UL5-containing transcripts, we performed a Northern blot analysis on the total RNA extracted 
from HCMV-infected cells at different times post infection (p.i.) using an UL5-specific 
biotinylated DNA probe. A band around 1.5 kb was detected, excluding the presence of 
further transcripts. To address the study of UL5 protein product (pUL5), a two-step 
mutagenesis was carried out on a bacterial artificial chromosome (BAC) containing the entire 
genome of the TR strain of HCMV to generate a recombinant virus with the addition of an 
optimized combination of tags (2StrepII-2FLAG) at the C-terminus of pUL5. pUL5 
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expression profile was studied by immunoblot on lysates of fibroblasts infected with the 
recombinant pUL5-tagged virus prepared at different times p.i. using an anti-FLAG antibody. 
Two species of approximately 24 and 15 kDa were detected with late and early expression 
kinetics, respectively. Since the predicted molecular weight of the entire tagged protein is 24.5 
kDa, the higher molecular weight form probably corresponds to the full-length protein. 
Glycosylation analysis of pUL5 both in transfection and in infection further confirmed the 
absence of glycosylation events. To investigate the nature of the lower molecular weight 
species, we performed a PCR site-directed mutagenesis to eliminate a second ATG in UL5 
ORF. Western blot analysis on lysates of HEK293T cells transfected with the mutated plasmid 
of UL5 revealed a strong reduction in the signal of the 15 kDa species. A recombinant form of 
pUL5 lacking the putative transmembrane region was expressed in E. coli, purified and used 
to obtain an antiserum in mice. Western blot on lysates of fibroblasts infected with the wild-
type virus using the mouse antiserum replicated the previous data, excluding a possible 
influence of the tags to the obtained results. Confocal microscopy of infected fibroblasts both 
with wild-type and recombinant viruses, implementing both the pUL5 antiserum and the anti-
FLAG antibody, localizes pUL5 with markers of the trans-Golgi network and secretory 
pathways, in the compartment of viral assembly. Western blot on purified virions failed to 
reveal the presence of pUL5, suggesting that this protein is only expressed in the host cell 
during infection but it is not incorporated in the released viral progeny. To have a deeper 
insight in pUL5 role during infection, an UL5 deletion mutant was generated by BAC 
mutagenesis and its ability to replicate in human fibroblasts was assessed. The knock-out 
mutant virus is still able to infect and replicate in fibroblasts but with a strongly reduced 
replication rate, suggesting an important role of pUL5 during HCMV infection. The 
recombinant pUL5-tagged virus was also implemented for a pull-down experiment to isolate 
potential interacting partners using anti-FLAG coupled magnetic beads. Mass spectrometry 
analysis allowed the identification of the cellular protein IQGAP1 as a pUL5 interactor. 
IQGAP1 is an ubiquitously expressed cellular protein involved in many cellular mechanisms, 
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such as cytoskeletal remodeling, cell adhesion, cell cycle regulation and Ca
2+
/Calmodulin 
signaling, and it is a known target of intracellular pathogens. This interaction was also 
confirmed by reciprocal immunoprecipitations in transfection, giving new hints on the 
possible role of pUL5 during HCMV infection. 
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CHAPTER I  
INTRODUCTION  
HUMAN CYTOMEGALOVIRUS GENERAL FEATURES, PATHOGENESIS AND 
CLASSIFICATION 
Human cytomegalovirus (HCMV) is a ubiquitous virus infecting the majority of adults 
worldwide, ranging around 55-60% of the world population, although reaching peaks of more 
than 90% seroprevalence in given populations grouped according to age-gender-
socioeconomic related factors [1]. Horizontal transmission depends on direct contact of 
infected bodily fluid at mucosal surfaces. In healthy individuals, a strong immune response to 
HCMV is able to limit and contain the spread of the disease, therefore bland clinical 
symptoms and spontaneous acute infection resolution are associated to infection of 
immunocompetent individuals [1]. Nevertheless, the virus is able to establish a lifelong lasting 
latency with recurrent and spontaneous reactivation and complete clearance of the virus by the 
organism is never achieved. Both innate and adaptive immune responses operate to control 
viral replication and spread. The acute disease associated with HCMV infection occurs only in 
a small proportion of infected individuals, in particular its onset is observed in patients where 
the normal immune response is compromised. For example, HCMV infection can lead to 
severe complications and death in the case of transplant patients when the immune system is 
shut down to avoid rejection of the organ [2]. Another example of opportunistic superinfection 
of HCMV is very common in patients with Acquired Immuno-Deficiency Syndrome (AIDS) 
following HIV infection; the immuno-deficient environment in these patients allows HCMV 
infection and/or reactivation [3]. Moreover, due to the HCMV ability to cross the trans-
placental barrier, congenitally acquired infection can pose a severe threat to the fetus that lacks 
a fully functional immune system. In all these particular cases, antiviral therapies are 
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necessary to counteract the severe disease associated to the HCMV primary infection or 
reactivation. Unfortunately, almost all antiviral agents actually on the market show a 
significant number of potential side effects including organ and marrow toxicity and the onset 
of increasing drug resistant viral strains [1]. To reduce the morbidity and mortality associated 
to HCMV infection in immunocompromised patients, a commonly implemented prophylactic 
tool is the passive immunization using hyper-immune globulin preparations with high levels of 
antibodies against HCMV (CMVIG). For example, combination of CMVIG and the antiviral 
drug ganciclovir proved to be effective in preventing HCMV infection in patients undergoing 
solid organ transplant [4]. Moreover, a study suggests their effectiveness in the treatment and 
prevention of severe diseases associated to congenital HCMV infection [5]. Nevertheless, the 
effectiveness and efficacy of CMVIG seem to be restricted to specific clinical cases while only 
modest beneficial effects were observed upon CMVIG treatment in other settings such as 
blood transfusion in premature newborns and hematopoietic cell transplantation (HCT) [6]. 
Some CMVIGs exhibit low potency in vitro [7] and must be administrated at high doses to 
exert a beneficial effect. To overcome this problem, a series of neutralizing monoclonal 
antibodies against immune-dominant HCMV envelope glycoproteins were developed. For 
example, a highly in vitro neutralizing antibody against glycoprotein H was isolated from the 
spleen of a CMV seropositive patient. The monoclonal antibody, named MSL-109 or 
sevirumab, was tested in phase II clinical trials as treatment for CMV-induced retinitis in 
AIDS patients [33]. Unfortunately the tests were stopped due to lack of efficacy [8].  
HCMV belongs to the Herpesviridae family, a classification historically based on the 
architecture of the virion that includes the herpesviruses of mammals, reptiles and birds. The 
Herpesviridae family is one of the three families, together with the Alloherpesviridae and the 
Malacoherpesviridae, encompassed by the Herpesvirales order, established later as extensive 
nucleotide sequence data became available [9]. The Herpesviridae family members share 
several biological properties, the most evident is the ability to establish latent infection in 
some cell types that usually vary among the different members. Moreover, in addition to 
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similar structural features, they share a large array of enzymes involved in nucleic acid 
metabolism, DNA synthesis and protein processing. Finally, in all Herpesviridae the DNA 
replication and capsid assembly occur in the nucleus, the final processing of the virion takes 
place in the cytoplasm and the release of the progeny results in the destruction of the host cell 
[1]. Among the Herpesviridae, the most common ones having human cells as their primary 
reservoir are: herpes simplex virus (HSV-1 and HSV-2), HCMV, varicella-zoster virus (VZV), 
Epstein-Barr virus (EBV), and Human herpesviruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-
8). The Herpesviridae family is itself composed of three subfamilies: the Alphaherpesvirinae 
(HSV-1, VZV), with a relatively short reproductive cycle and the ability the establish latent 
infection primarily in sensory ganglia, the Betaherpesvirinae (HCMV, MCMV), with a long 
reproductive cycle resulting in enlarged infected cells, and the Gammaherpesvirinae (EBV), 
usually specific for B and T lymphocytes and latent in the lymphoid tissue [10]. All 
betaherpesviruses exibit species specificity and only particular types of differentiated cells are 
susceptible within a species. All CMV are conveniently propagated in fibroblasts although 
natural targets include other cell types, such as epithelial, endothelial, macrophage and 
dendritic cells [11]. Unexpectedly, tropism is not determined by the distribution of cellular 
receptors on the host cells, in fact, non-permissive cells generally allow viral attachment and 
penetration, but viral replication is blocked at an early post-entry step [1]. 
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HCMV VIRION STRUCTURE AND GENOME ORGANIZATION 
 
Figure 1. (A) Schematic representation of HCMV virion (from  
http://drmhanna.com/cytomegalovirus-cmv/). (B) Negative stained purified virion preparation 
analyzed through electron microscopy.  
 
The HCMV virion is composed of an envelope, a tegument, and a capsid containing 
the double-stranded DNA genome. The virus envelope is a lipid bilayer derived from the host 
cell endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC) and contains the 
viral glycoproteins necessary for the cellular tropism [12]. Most functionally critical HCMV 
envelope glycoproteins are common to all herpesviruses and form three important complexes, 
termed gcI (glycoprotein B - gB - homodimer), gcII (gH:gL complex) and gcIII (gM:gN 
complex) [12-15]. Furthermore, two additional complexes of gH:gL have been observed, one 
including gO and probably involved in gH:gL-mediated fusion [16] and the other is a 
pentameric complex with UL128, UL130 and UL131 gene products and seems to be 
responsible for the specific tropism of some HCMV clinical isolates for epithelial, endothelial 
and dendritic cells [17, 18]. In comparison to the other herpesviruses, the envelope is highly 
irregular resulting in a viral shape whose diameter reaches up to 300 nm with an average size 
of 230 nm in diameter [19]. 
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Figure 2: HCMV envelope glycoprotein complexes. The proposed role of each complex is 
indicated in the respective box. Modified from [20]. 
 
 
The layer beneath the envelope is an amorphous matrix referred to as tegument. This 
compartment carries the majority of the HCMV expressed proteins plus a huge number of host 
species including proteins and nucleic acids. Tegument proteins are usually phosphorylated 
[13, 21] and cover several crucial viral functions including disassembly of the viral particle 
during entry, modulation of the host cell response to infection, alteration of the host cell cycle, 
and assembly of new particles, all aiming to the creation of an optimal intracellular 
environment for viral replication; among these are for example kinases, trans-activating 
factors and the most abundant and immunogenic protein pp65 [22]. 
The HCMV capsid is embedded in the tegument and contains a tightly packed linear 
double-stranded DNA genome. The complex of capsid and DNA is commonly named 
nucleocapsid. The icosahedral nucleocapsid is composed of five herpesvirus core proteins: the 
major capsid protein (MCP), the minor capsid protein and minor capsid protein binding 
protein (TRI1 and TRI2 respectively), the smallest capsid protein (SCP), and the portal protein 
(PORT) responsible for the encapsidation of the viral DNA [13]. Within infected cells, three 
mature capsid forms are observed, A, B, and C capsids. Only the latter type contains viral 
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DNA, while A and B capsids are usually found in the nucleus and cytoplasm of infected cells 
and are commonly referred to as non-infectious enveloped particles (NIEPs) [12, 13]. 
In line with the huge virus dimension, HCMV has the largest genome among its family 
with approximately 230 kb, 50% larger than HSV, despite the capsids of both viruses being 
roughly of the same size (110-125 nm) [23, 24]. The genome organization reflects the 
common structure of all herpesviruses, composed of unique long (UL) and unique short (US) 
genetic regions flanked by two sets of inverted repeats (RL, repeated long and RS, repeated 
short). Recombination phenomenon can occur among identical terminal and internal repeats, 
leading to genome isomerization. Thus, genetic material isolated from a viral population 
consists of equal amounts of four different genomic isomers pooled together [1]. While the 
general genomic arrangement is conserved among HCMV strains, a major difference in the 
open reading frame (ORF) organization and composition can be observed between 
“laboratory-adapted strains” and “clinical isolates” [25]. While laboratory strains indicate all 
the strains extensively passaged and adapted to growth in human fibroblasts, permitting easy 
manipulation due to the fast replication and high yields of produced virus, clinical isolates 
underwent through none or limited passages in cell culture before being cloned as bacterial 
artificial chromosomes (BACs) and/or sequenced. As a consequence of the fibroblast 
adaptation, severe genomic rearrangements occurred in laboratory adapted strains. Both 
Towne and AD169 laboratory strains acquired a large deletion of the UL segment, 
concomitantly being replaced by a duplication of the RL region. Due to these rearrangements, 
a difference in the coding potential can be observed between laboratory strains and clinical 
isolates. In particular, while the AD169 is predicted to encode for 208 ORFs (including the 
repeated segments), the coding potential of a clinical isolate is estimated around 252 ORFs [25, 
26]. Recently, through an integrated approach that combines ribosome footprinting assays and 
high-resolution mass spectrometry, Stern-Ginossar and co-workers reported no less than 751 
translated ORFs and 53 novel proteins originating from ORFs overlapping the known ORFs 
[27]. Despite this huge coding potential, only a small subset of these proteins constitutes the 
 17 
mature virion: it has been estimated that around 50 [1, 28] proteins are incorporated in the 
virion. 
 
Figure 3. HCMV genome organization. ORFs map of conventional laboratory strain AD169 
and clinical isolate. The AD169 genome (upper) carries TRL1-14 (green arrow), UL1-132 
(dark blue arrow), IRL14-1 (green arrow), IRS1 (red arrow), US1-36 (light blue arrow), and 
TRS1 (red arrow). In the clinical isolate RL1-14, (green arrow), UL1-151 (dark blue arrow), 
IRS1 (red arrow), US1-36 (light blue arrow), and TRS1 (red arrow) are present. Modified 
from [29]. 
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VIRAL REPLICATION 
 
Figure 4. HCMV lytic life cycle. (1) Binding of HCMV glycoproteins gB and gH to cellular 
receptors activates cellular transcription factors, such as NF-kappaB and Sp1. (2) The virus 
then enters the cell, releasing viral DNA, virion proteins and virion mRNA transcripts into the 
cytoplasm, where virion mRNAs are translated. Viral DNA and certain viral proteins are 
transported to the nucleus. (3) In the nucleus, viral and cellular genes are expressed, with help 
from the activated transcription factors, and viral DNA is replicated. (4) Viral DNA, viral and 
cellular proteins, and virion transcripts are packaged into the virion through an as yet 
undetermined mechanism. During egress of the virion from the cell, the virion envelope is 
constructed and an infectious viral particle is released. From [30]. 
 
HCMV replicates in many cell types, but most of the available information originates 
from studies conducted in primary or secondary fibroblasts, a stromal cell type that can be 
derived from any host tissue. In general, three main classes of gene expression determine the 
productive infection of HCMV in permissive cells: immediate early (IE), delayed-early (DE) 
and late (L) genes. Despite the slow replication cycle, requiring 48 to 72 hours for the progeny 
to egress, the expression of IE gene products begins immediately after viral entry [1]. This 
initial step consists in five consequential events: the binding of viral envelope glycoproteins to 
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specific cell surface receptors, the release of nucleocapsid into the cytoplasm mediated by the 
fusion of the viral envelope with the cellular membrane, the nucleocapsid association with 
cytoskeletal elements to promote translocation towards the nucleus, the nucleocapsid 
interaction with the nuclear pores and the release of the viral genome into the nucleus. 
 
Figure 5: Delivery of HCMV capsid to the nucleus. (A) HCMV capsid and associated 
tegument proteins are transported along the microtubules (B) toward the nucleus. A set of 
tegument proteins dissociate from the capsid and migrates independently to the nucleus (C). 
Viral DNA is released into the nucleus through the nuclear pores (D). Modified from [31].  
 
A relatively conserved feature among the herpesviral family is the engagement of 
heparin sulfate proteoglycans (HSPG) that is believed to initiate a cascade of events involving 
other entry mediators and cellular receptors [14]. The principle actor of this initial binding in 
HCMV infection is the gB homodimer. Apparently, the eterodimeric complex composed of 
the most abundant envelope glycoprotein, gM, and gN is also involved in HSPG tethering and 
stabilization of virus-cell contact. The gH-gL complex plays an important role in the fusion of 
the viral particle with the cell membrane and variable third components appear to be 
responsible for different cell tropisms: gO for fibroblasts and pUL128, pUL130 and pUL131 
for epithelial and endothelial cells and monocyte-macrophages tropism [32]. Various works 
describing the HCMV entry step suggest that the virus uses distinct cellular receptors, and 
consequently different entry pathways, depending on the target cell. Indeed, while direct 
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fusion at neutral pH has been observed in vitro in fibroblast cells [14], low pH dependent 
receptor-mediated endocytosis is required for viral entry in epithelial and endothelial cells [33]. 
Once the particle is released into the cytoplasm, regulatory tegument proteins dissociate from 
the capsid and either remain in the cytoplasm or migrate independently to the nucleus, where 
they modulate cellular and viral genes expression. A subset of tegument proteins remains 
tightly associated with the nucleocapsid and contributes to the delivery of the DNA to the 
nucleus by association with elements of the microtubular network (MT). HCMV 
nucleocapsids move from cellular periphery along MT branches up to the perinuclear MT 
organizing center (MTOC) to reach the nuclear pore complex and to inject the viral genome 
into the nucleus [34]. Almost immediately after the viral DNA has been delivered to the 
nucleus, IE genes expression ensues resulting in dramatic effects on the host cells. On the one 
hand, IE gene products act as global regulators of viral genes expression but they also promote 
several functions, such as cell death suppression or immune-evasion, important for viral 
pathogenesis. Delayed-early genes expression starts by 6 h post-infection and continues during 
viral DNA synthesis. Indeed, the majority of DE gene products are involved in viral DNA 
replication and in its fine regulation [35], while others are implicated in capsid maturation and 
modulation of the host cell response to infection. During this phase of infection, a gradual 
increase in HCMV DNA synthesis and a strong stimulation of the host metabolism are 
observed, while, at least in fibroblasts, the host cell cycle is blocked and no cellular DNA 
synthesis occurs [1]. Furthermore, many DE genes, together with L genes, encode for 
structural proteins or are involved in the final steps of the viral replication cycle, such as 
capsid maturation, DNA encapsidation and virion maturation and egress from the host cell. 
HCMV infection induces a global reprogramming of the cellular activity and causes dramatic 
changes in infected cell morphology. The most evident is the formation of two compartments: 
a nuclear replication inclusion where the viral DNA synthesis takes place and a large 
cytoplasmic juxtanuclear region defined virion assembly compartment (AC), responsible for 
the virus final envelopment and egress. Moreover, HCMV has developed a huge arsenal of 
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genetic functions committed to modulate both innate and adaptive immune responses. In 
particular, the virus is able to subvert the immune system mimicking the same strategies and 
mechanisms used by the host cells to clear the infection. Inhibition of complement cascade 
and natural killer (NK) cells activation, attenuation of interferon (INF) response and disruption 
of antigen presentation are only few examples of the functions hijacked by virus encoded 
chemokines, cytokine and cellular receptors homologues [36]. 
 
Figure 6. HCMV virion particles formation, maturation and budding processes. Major cellular 
and viral proteins involved in these processes are reported (red and blue, respectively). List of 
abbreviations: DB, dense body; VP, virus particle; EE/RE, early endosome/recycling 
endosome; LE, late endosome; GB, Golgi body; ER, endoplasmic reticulum; NP, nuclear pore; 
INM, inner nuclear membrane; ONM, outer nuclear membrane; A, B and C, types of nuclear 
capsids. From [29]. 
 
The final steps are common among the Herpesviridae family and involve a two-stage 
envelopment-deenvelopment-envelopment process that drives the nucleocapsid outside the 
nucleus to the AC to acquire the full spectrum of tegument proteins and envelope 
glycoproteins, and finally the mature virion to be released by exocytosis at the plasma 
membrane [12]. 
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CHAPTER I I  
CHARACTERIZATION OF pUL5, AN HCMV PROTEIN 
INTERACTING WITH THE CELLULAR PROTEIN IQGAP1 
ABSTRACT 
HCMV is a β-herpesvirus infecting the majority of population, usually establishing a 
lifelong latent infection. Immunosuppressive conditions, such as that of transplant, AIDS 
patients or newborns, allow reactivation of the virus, associated to a variety of diseases. 
Among herpesviridae, HCMV owns the largest genome and displays a huge coding potential. 
In this work, we address the study of the gene product of UL5 reading frame of the clinical 
isolate TR strain, present as a single copy in both clinical isolates and laboratory adapted 
HCMV genomes. The putative protein product is a 166-amino-acid membrane protein with a 
theoretical mass of 19 kDa. Northern blot analyses showed that the gene was transcribed with 
early kinetics together with UL4 reading frame. Recombinant virus expressing pUL5 with a 
tag at the C-terminus of the protein allowed the identification of two pUL5 non-glycosylated 
species of approximately 24 and 15 kDa, expressed with late and early kinetics, respectively. 
Experiments in transfection suggest that the lower molecular weight species could be the 
result of the translation from a second ATG in UL5 reading frame. Confocal experiments 
carried out both with the recombinant and with the wild-type virus localize pUL5 in the 
assembly compartment, but western blot on purified virions failed to identify the protein, 
suggesting that pUL5 is only expressed in the host cell during infection. Furthermore, UL5 
deletion resulted in an impaired replication of the virus in human fibroblasts with respect to 
the wild-type virus. Finally, pull-down experiments coupled with mass spectrometry analysis 
identified IQGAP1 as a pUL5 interactor, and this was also confirmed by reciprocal 
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immunoprecipitations in transfection, giving new hints on pUL5 possible roles during HCMV 
infection.  
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INTRODUCTION 
HCMV is a ubiquitous, highly specific herpes virus, infecting as many as 75% of 
adults. It establishes latent infection adapting numerous immune evasion strategies. Despite 
being normally relatively benign, HCMV infection can induce severe disease in 
immunocompromised patients, and in fetuses in the case of primary maternal infection [1]. 
HCMV infects a wide spectrum of cell types using different sets of surface molecules.  This 
heterogeneity suggests a very complex mechanism of recognition between the viral particle 
and the host cell. To obtain deeper insights of the mechanisms involved in HCMV infection, 
tropism, immune evasion and latency, it is yet required to study HCMV proteome. 
HCMV displays a coding capacity that far exceeds that of most other Herpesviridae, 
having the largest genome among all known human viruses. Its 240-kb double-stranded linear 
DNA genome is composed by a long unique (UL) and a short unique (US) sequences, each 
flanked by inverted repeats, named terminal or internal based on their position (TRL/IRL and 
TRS/IRS), giving the overall genome configuration TRL-UL-IRL-IRS-US-TRS [2]. Within the 
Herpesviridae family, sequence variability is very high but the gene content is quite conserved, 
with a set of core genes involved in metabolic and structural functions shared by all members. 
On the other hand, each member of this heterogeneous virus family carries some private genes. 
In most cases, these genes are dispensable for viral replication in cell culture and are usually 
involved in viral tropism or in the evasion from the immune system. Among them, the RL11 
gene family includes 11 genes present only in human and chimpanzee cytomegaloviruses, and 
3 genes only present in HCMV [3]. A common characteristics of this family is the RL11 
domain (RL11D), an immunoglobulin-like domain shared by the majority of the members of 
the RL11 family [4]. Belonging to this family are: two receptors for the Fc domain of 
immunoglobulin G, RL11 and RL13 [5, 6], three are envelope-associated glycoproteins (UL4-
encoded gp48, UL1 and RL13) [7-9]. The product of UL11 gene is a hypervariable protein 
expressed on the surface of infected cells [10, 11]. UL7 encodes for a SLAM-family receptor 
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CD229 homologue that impairs cytokine production and promotes angiogenesis [12, 13]. In 
general, RL11 family members share some common features, in particular that of membrane-
associated glycoproteins and the RL11D with some exceptions: UL4, RL5 and RL6 for 
example lack the transmembrane region [3, 8]. 
In the present study, we have approached the structural and functional characterization 
of UL5, member of the RL11 family that lacks the RL11D and appears to be N-terminally 
truncated with respect to the other RL11 family members. To this goal, we produced a 
recombinant HCMV virus adding a combination of tags (two StrepII and two FLAG tags) at 
the C-terminus of UL5 protein product by BAC mutagenesis of the TR strain genome of 
HCMV in E. coli, and a deletion mutant lacking the entire UL5 open reading frame (ORF). 
Our data indicate that pUL5 is an early expressed protein that is not incorporated into the viral 
particle but localizes in the assembly compartment of the infected cell. Furthermore, we 
demonstrated that UL5 deletion results in impaired replication in human fibroblasts and that 
during infection it interacts with the cellular scaffold protein IQGAP1. 
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RESULTS AND DISCUSSION 
UL5 OPEN READING FRAME AND ITS PREDICTED PROTEIN PRODUCT  
The UL5 ORF is found as a single copy in the HCMV genome, within the unique long 
region, approximately 2 kb from the junction with the terminal repeat long region. According 
to sequence similarity,  UL5 has been classified as a member of the RL11 multigene family [4]. 
This family consists of 14 genes (RL5A, RL6, RL11, RL12, RL13, UL1, UL4, UL5, UL6, UL7, 
UL8, UL9, UL10, UL11) distributed contiguously in the long repeats and in the unique long 
region, aligned from 5’ to 3’ orientation with this order. There are two additional ORFs (UL2 
and UL3) identified on the opposing strand between UL1 and UL4 as unrelated genes [3]. The 
RL11 family is defined by the RL11 domain, a region of variable length with three conserved 
residues (a tryptophan and two cysteines) that resembles a domain shared by some members of 
the immunoglobulin superfamily [4]. Despite being an RL11 family member, UL5 lacks an 
RL11 domain and is N-terminally truncated but does have a transmembrane domain. All RL11 
genes are absent in cytomegaloviruses of other animal species, with the exception of 
chimpanzee cytomegalovirus (CCMV) that contains counterparts of all but UL1 [3]. UL5, 
therefore, is only present in human and chimpanzee cytomegaloviruses while is absent in 
cytomegaloviruses infecting other species [2]. 
In order to investigate UL5 ORF and the similarity of amino-acid sequence among 
different HCMV strains, a multiple alignment was performed using CLUSTALW server [14]. 
In the alignment both laboratory adapted strains and clinical isolates are compared, showing 
that the overall sequence is conserved and major differences belong to the N-terminal part of 
the predicted protein (Fig. 1A). 
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Figure 1. (A) Alignment of UL5 amino acid sequences of clinical isolates and laboratory 
adapted strains. Numbers above the sequences represent amino acid residues. (B) Structural 
prediction of HCMV UL5 protein. Transmembrane region and predicted O-glycosylation sites 
are indicated. 
 
 
UL5 ORF is predicted to encode a 166 amino-acid protein. Analysis with PSORT 
server [15] identified a transmembrane region between amino-acids 118 and 134, suggesting 
that pUL5 is a type Ib membrane protein with the C-terminus exposed in the cytoplasmic 
region and the N-terminus exposed towards the lumen or extracellular space. PSORT analysis 
also excluded the presence of a signal peptide. This prediction was further corroborated by the 
SIGNALP server prediction [16]. Since many RL11 family members are predicted or have 
been identified as membrane glycoproteins [6, 9-11], the glycosylation prediction was also 
investigated using NetNGlyc [17] and NetOGlyc [18] servers. pUL5 is not predicted to have 
N-glycosylation sites while 7 potential sites of O-glycosylation are present (Fig. 1B).  
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UL5 TRANSCRIPTION 
According to literature, UL5 coding sequence is included in three bigger transcripts 
containing also UL4 ORF and transcribed from three promoters with different kinetics [8, 19]. 
UL4 protein product, also called gp48, is a glycoprotein expressed in the early phase of 
infection that seems to have a very complex regulation, at the transcription level as well as the 
translation, due to an upstream ORF present in the same transcripts [20, 21]. To date, no 
information is available on the protein product of UL5 ORF. 
In order to investigate the transcription profile of the UL5 ORF, total RNA was 
isolated from human foreskin fibroblast (HFF) cells at different time points after infection 
with HCMV TR and subjected to Northern blot analysis using a UL5 mRNA-specific 
biotinylated DNA probe. The probe detected a single transcript of 1.5 kb already visible at 6 
hours post infection (p.i.) (Fig. 2). This is consistent with the information available in 
literature, confirming that UL5 mRNA is part of a bicistronic transcript with UL4 and 
excluding the presence of another transcript containing UL5 alone. In fact, also the promoter 
prediction analysis failed to identify putative promoters between UL4 and UL5 coding 
sequences (data not shown). 
 
Figure 2. UL5 gene transcription. Northern blot of whole-cell RNA isolated from uninfected 
(C) or TR infected fibroblasts at the indicated times post-infection with a UL5-specific probe. 
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CONSTRUCTION OF UL5-TAGGED RECOMBINANT VIRUS 
In order to investigate UL5 protein product in the contest of infection, we applied a 
two-step Red-Gam mediated mutagenesis on a BAC containing the entire genome of HCMV 
TR strain [22] to obtain a recombinant virus carrying a tag at the C-terminus of UL5 protein. 
Briefly, this strategy consists of two recombination steps: the first allows the integration of the 
tag together with the expression cassette for kanamycin resistance, while in the second step, 
digestion with I-SceI enzyme permits the alignment of homologous sequences and the 
excision of the kanamycin resistance cassette, leaving the tag in-frame with the C-terminus of 
pUL5. This is achieved with the implementation of the E. coli strain GS1783 containing the 
TR BAC, the lambda Red system expressed with a heat-inducible promoter and the I-SceI 
enzyme expression cassette under the control of a promoter inducible with arabinose. 
Initially, this strategy was implemented with a cassette amplified from pEP-KanS 
vector that allows the adding of a FLAG tag at the C-terminus of the protein of interest. After 
several attempts, we concluded that this was not the optimal tag for UL5 protein detection and, 
therefore, we constructed a new cassette for recombination that could permit the modification 
of the protein of interest with multiple combinations of tags in order to identify the best tag for 
UL5 protein. This cassette was designed in a palindrome manner (Fig. 3), so that the 
amplification of the fragment indicated by the upper arrow would result in the adding of V5 
and streptavidin-binding peptide (SBP) tags, while the amplification of the opposing strand as 
indicated by the lower arrow would add two StrepII and two FLAG tags at the C-terminus of 
the protein of interest. Furthermore, in addition to the possibility of testing different tags for 
UL5 protein detection, this strategy allows also the implementation of the tandem-affinity 
purification (TAP), i.e. the sequential purification of a protein by affinity binding to different 
tags, in order to isolate UL5 protein together with its interacting partners. In fact, it has been 
shown that these combinations of tags have given the best results when used for mammalian 
proteins immunoprecipitations [23]. 
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Figure 3. Recombination cassette of pEP-TAP. The cassette is designed for the differential 
tagging of a selected protein, giving the chance to introduce V5 and SBP tags if amplified as 
indicated by the upper arrow or two StrepII and two FLAG tags if amplified as shown by the 
lower arrow. 
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UL5 PROTEIN EXPRESSION 
The expression of UL5 protein product during HCMV infection was investigated using 
the recombinant virus with a tagged-UL5 protein. To this purpose recombinant infectious 
viruses were used to infect HFF cells at multiplicity of infection (MOI 5). Lysates were 
prepared at different times post-infection (p.i.) and subjected to immunoblot using anti-tag 
monoclonal antibodies to assess the presence of UL5. The best signal was obtained using the 
anti-FLAG monoclonal antibody on lysates of TR-UL5-2StrepII-2FLAG infected HFF cells 
(Fig. 4). HCMV lytic gene expression is conventionally divided into three major kinetic 
classes of viral genes, immediate-early, early, and late. Monoclonal antibodies against HCMV 
immediate-early antigen 1 (IE1) and gB (late gene) were used as references for the expression 
kinetics and GAPDH as a loading control. Two species of approximately 24 and 15 kDa were 
detected starting 48 h p.i with different expression patterns. The lower molecular weight 
species is already fully expressed at 48 h p.i. while the higher is less expressed. Both species 
are absent at 24 h p.i. while IE1 is already visible, demonstrating that pUL5 is not expressed 
with an immediate-early kinetics. Apparently, the higher molecular weight form of pUL5 
shows an expression profile similar to that of gB, consistent with a late expression profile, 
while the lower molecular weight form appear to be expressed with an early kinetics.  
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Figure 4. Expression of UL5 protein in HCMV-infected fibroblasts. Western blot on lysates 
of HFF cells infected with TR UL5-2StrepII-2FLAG or TR (negative control - C) at an MOI 
of 5, prepared at the indicated times p.i. pUL5 was detected with an anti-FLAG monoclonal 
antibody; anti-IE1 and anti-gB monoclonal antibodies were used as markers for immediate-
early and late expression kinetics, respectively, while GAPDH detection was used as a protein 
loading control. 
 
 
The predicted molecular weight for the tagged protein is 24.5 kDa, consistent with the 
higher band present in the Western blot. This suggests that both forms do not undergo 
glycosylation. To confirm this, HEK-293T cells were transfected with pcDNA-UL5-c-myc-
6his (calculated molecular weight 22 kDa). Lysates were treated with EndoH, PNGaseF and 
O-glycosidase as described in the material and methods section, subjected to SDS-PAGE and 
immunoblot using an anti-his tag monoclonal antibody (Fig. 5A). As expected, no band shift 
was observed after the treatment, demonstrating that neither form of pUL5 is glycosylated. To 
confirm that no glycosylation occurs even in the contest of infection, HFF cells were infected 
with HCMV TR-UL5-2StrepII-2FLAG at MOI 3. 72 h p.i. cell extracts were prepared and 
treated with the same enzymes (Fig. 5B). Similar results were obtained, confirming that UL5 
protein product is not glycosylated. 
 
Figure 5. Glycosylation analysis of UL5 protein. Lysates from HEK-293T cells transfected 
with pcDNA-UL5-c-myc-6his (A) or from TR UL5-2StrepII-2FLAG infected HFF cells (B) 
were treated with Endoglycosidase H, Peptide N-glycosidase F (PNGase F) or O-glycosidase 
and subjected to SDS-PAGE and immunoblot with anti-his (A) or anti-Flag (B) monoclonal 
antibodies. 
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A possible explanation of the two different species of UL5 protein is the presence of a 
second ATG within UL5 coding sequence. The predicted molecular weight of the amino-acid 
sequence from the second methionine (Met87) is 15 kDa, consistent with the lower molecular 
weight species detected by immunoblot both in transfection and infection environments. To 
test this hypothesis, a site-directed mutagenesis was carried out on the pcDNA-UL5-c-myc-
6his, changing the ATG codon for Met87 to GCG. HEK-293T cells were transfected with 
pcDNA-UL5-M87A-c-myc-6his and lysates were subjected to SDS-PAGE and immunoblot 
using an anti-his tag monoclonal antibody. As seen in figure 6, the mutation M87A resulted in 
a strong reduction of the expression of the lower molecular weight species of UL5, suggesting 
that this form is translated from Met87. 
 
Figure 6. HEK-293T cells were tranfected with pcDNA-UL5-c-myc-6his or pcDNA-UL5-
M87A-myc-6his and subjected to SDS-PAGE and immunoblot using an anti-his monoclonal 
antibody. 
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pUL5 ANTISERUM PRODUCTION 
The addition of a combination of four tags (two StrepII and two FLAG tags) to a per-se 
very small protein could result in many misinterpretations. For example, the biochemical 
characteristics of the tagged protein as well as the subcellular localization and trafficking 
could be perturbed by the presence of this 54 amino-acids tail. We therefore needed a tool for 
the detection of wild-type UL5 protein during infection, in order to exclude the possibility of a 
different behavior of the protein due to the addition of the tags.  To this end, we produced a 
recombinant his-tagged form of UL5 protein lacking the putative transmembrane region in E. 
coli BL21(DE3) strain and affinity purify it from the insoluble fraction using a NiNTA 
sepharose resin. The purified recombinant protein, obtained with good yield and purity as can 
be seen in figure 7, was formulated with Freund’s adjuvant and used to immunize mice, as 
described in the material and methods section, to obtain an anti-UL5 serum. 
 
Figure 7. SDS-PAGE of 5 µg (lane 1) or 13 µg (lane 2) of purified recombinant UL5ΔTM. 
 
 
  
 40 
LOCALIZATION OF pUL5 
In order to investigate the subcellular localization of pUL5 during infection, both anti-
FLAG monoclonal antibody and the antiserum raised in mice were used to immuno-detect the 
protein by confocal microscopy in comparison with markers of the trans-Golgi network and 
secretory pathway (TGN46) and glycoprotein H (gH). As displayed in Fig. 8, UL5 protein co-
localizes with TGN46 and gH, suggesting that the protein accumulates in the assembly 
compartment (AC), where the virus particles are generated. HCMV infection changes the 
morphology of the nucleus which becomes larger and wraps around this juxtanuclear 
compartment through reorganization of cellular organelles including the endoplasmic 
reticulum, the Golgi apparatus, secretory vesicles and the early endosomes, as well as the 
lysosomes [24]. In this compartment, the nucleocapsids transported from the nucleus associate 
with tegument and envelope proteins with a mechanism that is not yet well understood [25]. 
Furthermore, we can affirm that there are no differences between the tagged (second and third 
rows of panels – Fig 8) and untagged (first row of panels – Fig 8) forms of pUL5, 
demonstrating that the addition of the tags does not affect the protein localization. 
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Figure 8. Subcellular localization of pUL5 in infected cells. Confocal imaging of HFF cells 
infected with the TR wild-type virus (first row) or with the recombinant UL5-2StrepII-2FLAG 
virus (second and third rows) at an MOI of 5 and fixed at 96 h p.i. The intracellular 
localization was determined by comparing the signal from pUL5 antiserum raised in mice or 
FLAG-specific antibody M2 (pUL5) with those of antibodies specific for HCMV envelope 
glycoprotein H and TGN46, a component of the secretory pathway trans-Golgi network. The 
merge panel shows the colocalization of the signals, cell nuclei are also stained blue. 
 
  
Since pUL5 localizes in the AC during infection, we wondered whether it is also 
incorporated into the viral particles. To address this question, supernatants from TR-UL5-
2StrepII-2FLAG HCMV infected fibroblasts were subjected to a sodium/tartrate gradient 
ultracentrifugation and mature virions were isolated and separated into the envelope and 
tegument fractions as described in the materials and methods section. The fractions were 
subjected to SDS-PAGE and immunoblot using an anti-FLAG antibody to detect the presence 
of UL5 protein, anti-glycopretein B and anti-pp65 antibodies were used as controls (Fig. 9). 
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Figure 9. Western blot of envelope and tegument fractions of purified mature TR-UL5-
2StrepII-2Flag HCMV virions. Anti-FLAG monoclonal antibody was used to reveal pUL5 and 
anti-glycoprotein B and anti-pp65 were used as controls. 
 
As expected, glycoprotein B is only found in the envelope fraction while pp65 is 
almost entirely detected in the tegument fraction. In fact, pp65 is the most abundant (up to 15% 
of the tegument protein content) and immunogenic protein of the HCMV tegument [26]. 
Neither the anti-FLAG antibody (Fig. 9) nor the pUL5 anti-serum (data not shown) was able 
to detect UL5 protein in purified virions. Immunoblot analysis was performed both on the 
complete virions and dense bodies and also on separate tegument and envelope fractions and 
in no cases UL5 protein was identified. In 2004 Varnum et al. published a study that aimed to 
charachterize the HCMV virion proteome [26]. In this study, Varnum and coworkers were 
only able to detect a single pUL5 peptide by Fourier transform ion cyclotron resonance 
(FTICR) mass spectrometry in purified virions, while the less sensitive two-dimensional 
capillary liquid chromatography-tandem mass spectrometry (LC-MS/MS) failed to identify 
any pUL5 peptide. Together these data suggest that pUL5 is not a structural component of the 
HCMV virion and, probably, the single pUL5 peptide identified by Varnum and coworkers is 
the result of a random incorporation of pUL5 into the mature virion. In fact, it is very common 
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that several cellular and viral elements, including proteins, small molecules and RNAs, are 
randomly included in the virions [27]. 
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DELETION OF UL5 RESULTS IN INPAIRED REPLICATION IN HUMAN 
FIBROBLASTS 
In 1991, Ripalti et al. published that all products of HCMV genes UL1-UL7 are 
dispensable for viral growth in cell culture [28]. In order to confirm this and have an insight in 
pUL5 role during HCMV infection, a UL5 deletion mutant was constructed by BAC 
mutagenesis as described in the materials and method part. The replication kinetics of the 
deletion mutant was compared with the wild-type TR HCMV to assess whether the absence of 
pUL5, despite being dispensable, had an effect on viral replication. Fibroblasts were infected 
in 12-well plates and infectious supernatants were harvested at different time points p.i. and 
titrated by IE-1 immuno-detection. In Fig. 10 the replication kinetics, expressed as infectious 
units per ml over time, of the UL5 deletion mutant and the wild type viruses are shown. 
 
Figure 10. Replication kinetics of UL5 deletion mutant virus with respect to the TR wild-type 
virus. At the indicated days p.i., supernatants from the infected cultures were harvested and 
titrated using indirect immunofluorescence with an antibody directed against IE1. The 
experiment was repeated two times, and a representative result is shown. 
 
As Fig. 10 shows, it is evident that the absence of UL5 ORF has a strong impact on the 
replication kinetics of the virus, decreasing the overall titer by two logs and showing a reduced 
rate constant. This may be either a direct effect or a polar effect of the mutation on the genes 
up and downstream UL5 ORF, for example changing the stability of the UL4-UL5 bicistronic 
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transcript or deleting sequences included in UL5 ORF that could be involved in the regulation 
of other proteins expression. In order to confirm that this phenotype is a direct effect of the 
UL5 protein missing, further experiments complementing pUL5 are needed. 
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pUL5 INTERACTS WITH IQGAP1 
The impaired replication of UL5 deletion mutant in contrast to the wild-type TR 
HCMV suggests an important role of UL5 protein in viral replication. To better understand the 
role of UL5 protein during HCMV infection and the reasons of why deleting UL5 ORF results 
in an impaired replication, we searched for pUL5 interactors through a pull-down experiment 
coupled with mass spectrometry analysis. To this end, fibroblasts were infected with TR-UL5-
2strepII-2FLAG and with TR wild-type (negative control) HCMV at MOI 3. Lysates were 
prepared at four days p.i. and subjected to immuno-precipitation (IP) using anti-FLAG 
monoclonal antibody-coupled magnetic beads as described in the materials and methods 
section. The eluted fractions were then run on SDS-PAGE and stained with colloidal 
Coomassie (Fig. 11A). Part of the samples was also controlled by Western blot to assess the 
presence of the immuno-precipitated pUL5 only in the TR-UL5-2strepII-2FLAG sample and 
its absence in the control using an anti-FLAG monoclonal antibody (Fig. 11B). 
 
Figure 10. Pull-down of UL5-strepII-2FLAG from lysates of HFF cells infected with the 
recombinant virus and the control. Eluted fractions of the pull-down were subjected to SDS-
PAGE and stained with colloidal coomassie (A) or revealed by immunoblot with anti-FLAG 
monoclonal antibody (B). 
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Fig. 11A shows that the pattern of the immuno-precipitation is very similar in the 
sample with respect to the control, with the exception of one high molecular weight species 
indicated by the red arrow. In order to identify it, the band of this species and the 
corresponding slice in the control sample were cut, digested with trypsin and analyzed by 
mass spectrometry. The resulting spectra were searched on Mascot database (MatrixScience) 
and 18 peptides of the cellular protein IQGAP1 were identified in the sample and none in the 
control. In order to confirm this interaction HEK-293T cells were transfected with pcDNA-
UL5-c-myc-6his and reciprocal IPs were carried out using Dynabeads
®
 protein G with anti-c-
myc, anti-IQGAP1 and anti-GAPDH (negative control) antibodies as described in the 
materials and methods.  Samples were run in SDS-PAGE and revealed by immunoblotting 
using the same antibodies (Fig.12).  
 
Figure 12. Immunoprecipitation of UL5 protein and IQGAP1. Lysates of HEK-293T 
transfected with pcDNA-UL5-c-myc-6his were immuno-precipitated with Dynabeads® 
Protein G using anti-IQGAP1, anti-c-myc or anti-GAPDH monoclonal antibodies. Eluted 
fractions were analyzed by SDS-PAGE and immunoblot with the indicated antibodies. 
 
The IP of pUL5 with the anti-c-myc antibody co-precipitated IQGAP1, confirming the 
pull-down, and viceversa the IP with the anti-IQGAP1 antibody co-immunoprecipitated pUL5. 
On the other hand, IP with an unrelated antibody, anti-GAPDH, failed to precipitate both 
pUL5 and IQGAP1. We therefore concluded that pUL5 is a new IQGAP1 interactor.  
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IQGAP1 is a ubiquitously expressed scaffold protein which participates in multiple 
cellular processes [29], including Ca
2+
/Calmodulin signalling, cytoskeletal organization, 
CDC42 and Rac signalling, E-cadherin-mediated cell–cell adhesion and β-catenin-mediated 
transcription [30]. It is composed of four domains: a calponin homology domain (CHD) that 
binds F-actin, a WW domain, a tandem repeat of four IQ motifs binding calmodulin and the 
GAP-related domain (GRD) mediating the binding of the Rho GTPases, CDC42 and Rac1 
[30]. Despite the name, IQGAP1 lacks GTPases activating protein (GAP) activity, in fact it 
inhibits CDC42 GTPase activity stabilizing the receptor in its active state [31]. Overall, 
IQGAP1 has a key role in the modulation of actin cytoskeleton through its interaction with 
Rac1 and CDC42. Furthermore, IQGAP1 is deeply involved in cell–cell adhesion and 
migration [31]. It is, therefore, of no surprise that IQGAP1 is a common target for intracellular 
pathogens. For example, Salmonella typhimurium modulates IQGAP1 and its binding to both 
Rac1/Cdc42 and actin to gain entry into host cells. Furthermore, Ca2+/calmodulin signaling 
by enteropathogenic E. coli (EPEC) to induce actin pedestal formation is mediated entirely 
through IQGAP1 [32]. IQGAP1 has been also identified as a viral target during Ebola egress 
from the host cell [33]. Since this protein is involved in so many cellular mechanisms, pUL5 
interaction with IQGAP1 could have several purposes. UL5 protein localizes in the AC during 
infection, this could suggest a role of pUL5 in the formation of this compartment by 
interacting with a cytoskeleton regulator. Further experiments are needed in order to 
understand biological and pathological meaning of this interaction. 
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CONCLUSIONS 
We have investigated the protein product of UL5, a previously uncharacterized ORF of 
HCMV genome. UL5 is classified as an RL11 family gene and is predicted to encode for a 
type Ib membrane protein with no signal peptide and 7 potential O-glycosylation sites. 
Northern blot analysis with a UL5-specific probe identified a single 1.5 kb mRNA transcribed 
with early kinetics, in line with what was reported in literature about a UL4-UL5 co-transcript. 
By BAC mutagenesis we were able to produce recombinant viruses with a tagged version of 
UL5 protein allowing the identification of two forms of approximately 24 and 15 kDa 
expressed with late and early kinetics, respectively. We also demonstrated that neither form of 
UL5 protein is glycosylated and we suggest that the lower molecular weight species is the 
result of the translation starting from a second ATG of UL5 ORF. Furthermore, Western blot 
on purified HCMV virions failed to identify UL5 protein as a structural component, 
suggesting that this protein is only expressed in the host cell during infection. Confocal 
experiments localize pUL5 with markers of the TGN and secretory pathways and with gH in 
the AC. We also studied the replication kinetics of the UL5 deletion mutant virus, obtained by 
BAC mutagenesis, which showed a reduced replication rate in comparison to that of the wild-
type virus. Finally, pull-down experiments coupled with mass spectrometry analysis identified 
the cellular scaffold protein IQGAP1 as a UL5 protein interactor and reciprocal IPs in 
transfection further confirmed this interaction. Further studies are needed to understand the 
function of pUL5 during HCMV infection. 
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MATERIALS AND METHODS 
Cells lines and antibodies. Human foreskin fibroblast (HFF), human fetal lung 
fibroblast (MRC-5) and human embryonic kidney 293 (HEK-293T) cell lines were purchased 
from ATCC (catalogue numbers SCRC-1041, CCL-171 and CRL-11268 respectively) and 
cultured according to supplier’s instructions. Dulbecco’s modified Eagle’s medium (DMEM) 
high glucose (Gibco, Life Technologies) was supplemented with 10% fetal calf serum (FCS) 
and penicillin streptomycin glutamine (Gibco, Life Technologies).  
Primary antibodies used were: mouse anti-Flag (Sigma-Aldrich), mouse anti-6His 
(Life Technologies), mouse anti-c-myc (Life Technologies), rabbit anti-FLAG (Sigma-
Aldrich), mouse anti-pp28 (Vyruses), mouse anti-gH (AbD Serotech), sheep anti-TGN46 
(AbD Serotech), mouse anti-PDI (Life Technologies), rabbit anti-PDI (Abcam), mouse anti-
EEA1(Abcam), rabbit anti-EEA1 (Abcam), mouse anti-gB (Abcam) and mouse anti-GM130 
(Abcam)  monoclonal antibodies. Secondary antibodies used were: Alexa Fluor F(ab)2 
fragment of 488-, 568-, 647- conjugated goat anti-mouse/anti-rabbit (Life Technologies) and 
horseradish peroxidase-conjugated secondary antibodies from Perkin Elmer. Wheat Germ 
Agglutinin (WGA) 647-conjugated was purchased from Life Technologies. 
Viruses. Wild-type (WT) HCMV (TR strain) was derived from a bacterial artificial 
chromosome (BAC) containing the HCMV TR genome. The BAC TR was used to create 
recombinant viral genomes via a marker-less two-step RED-GAM BAC mutagenesis [22]. 
Briefly, kanamycin resistance cassette, flanked by I-SceI restriction enzyme cleavage sites, 
was amplified from pEP-TAP shuttle vector using primers containing homologous regions for 
the integration in the region of interest. All the primers used are listed in Table 1. 
Recombination events were performed with E. coli GS1783 strain containing a BAC clone of 
the HCMV TR strain, the lambda Red system under the control of a heat-inducible promoter 
and the I-SceI genes under the control of an arabinose-inducible promoter. The first 
recombination step consists in the electroporation of the purified PCR-amplified cassette in 
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competent, heat-induced GS1783 cells. Positive clones for cassette integration were selected 
based on kanamycin resistance and screened both by PCR and sequencing. The second 
recombination was triggered through both heat-shock and arabinose and results in the excision 
of the kanamycin resistance, leaving the tag sequence (V5-Streptavidin binding peptide or 
2xstrepII-2xFLAG) in frame with the C-terminus of the gene of interest. Presumptive clones 
were screened by PCR and sequencing, while the integrity of the recombinant HCMV genome 
was assessed through HindIII and BamHI restriction analysis. To reconstitute the virus, 
actively growing MRC-5 cells from a nearly-confluent T175-flask were trypsin detached, 
mixed with about 3 μg fresh prepared BAC DNA and 1 μg pCMVKm2-pp71 plasmid and 
electroporated in 4 mm cuvettes at 250 V and 950 μF. Supernatant was collected from infected 
cells when cytopathic effect was >90%. For all following infections, HFF cells were used. 
UL5 RNA analysis. For Northern blot analysis, whole-cell RNA was isolated from 
mock-infected or infected HFF cells at 6, 24, 48, and 72 h postinfection (p.i.) using RNeasy 
minikit (Qiagen). 10 µg of each sample were separated on 1% agarose gels and Northern blot 
analysis was carried out using NorthernMax
®
 kit (Life Technologies). 500 ng of each sample 
was also run on a separate gel as a control. Hybridization and detection were performed by 
using the BrightStar
®
 BioDetect™ kit (Life Technologies) according to the manufacturer’s 
instructions. Briefly, UL5-specific DNA hybridization probes were labeled with biotin-16-
dUTP (Roche) by PCR with UL5-specific primers UL5-NB-F and UL5-NB-R (Table 1), using 
TR BAC as a template. The PCR mix was prepared with 40% of biotinylated dUTP and 60% 
of dTTP. 
Preparation of eukaryotic expression constructs and DNA transfection. 
Lipofectamine 2000 (Life Technologies) was used to transfect HEK-293T cells according to 
manufacturer’s instructions. Human codon-optimized UL5 gene, from HCMV TR strain, was 
synthesized by Geneart (Life Technologies) and cloned in plasmid pcDNA3.1(-)/c-myc/6HisA 
(Life Technologies) in frame with C-term c-myc and six histidine tag sequences. pUL5 soluble 
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form was obtained by deleting the putative trans-membrane region (nucleotides 319 to 498) 
from the pcDNA3.1(-)UL5/c-myc/6HisA using Quickchange
®
 site directed mutagenesis 
(Stratagene) according to manufacturer’s instructions with primers UL5ΔTM-F and 
UL5ΔTM-R (Table 1). Correct deletion was confirmed by DNA sequencing. Mutation of the 
second ATG in UL5 open-reading frame (Met87) was obtained with the same strategy using 
primers UL5-M87A-F and UL5-M87A-R (Table 1). 
Production of recombinant his-tagged proteins in E. coli and antisera. All 
constructs for recombinant protein expression in E. coli were cloned using the Polymerase 
Incomplete Primer Extension (PIPE) method [34] with KAPA HiFi HotStart ReadyMix 
(kapabiosystems). Insert PCR for UL5ΔTM was amplified from pcDNA3.1(-)UL5ΔTM/c-
myc/6HisA with primers UL5Ec F and UL5Ec R, listed in Table 1, treated with DpnI (New 
England Biolabs - NEB) to eliminate the template and purified using Wizard
®
 SV Gel and 
PCR Clean-Up System. Vector PCR of pET15Tev was amplified with the primers petTEVfor 
and petTEVrev. Vector and DpnI-treated Insert PCRs were transformed in Mach1™ 
competent cells (Life Technologies). Positive clones were screened by colony PCR and 
sequencing. About 150 ng of plasmids were transformed in BL21(DE3) competent cells for 
recombinant protein expression using EnPresso™ B system (Biosilta) according to 
manufacturer’s instructions. The lysis was performed by sonication and the recombinant 
proteins were purified from inclusion bodies on a Ni sepharose HisTrap column (GE 
Healthcare). pUL5 was solubilized in Urea 8M and purified in denaturing conditions. Briefly, 
the resin was equilibrated with 10 column volumes (CV) of Binding buffer (20 mM Tris-HCl, 
300 mM NaCl, 10 mM Imidazole, 8 M Urea, 5 mM di-tio-tritole pH 8.0) before loading the 
sample, after binding step 20 CV of Binding buffer were used for washing step. Protein was 
eluted in 1 mL fractions with Elution buffer (20 mM Tris-HCl, 300 mM NaCl, 300 mM 
Imidazole, 8 M Urea, 5 mM di-tio-tritole pH 8.0). Protein purity was evaluated by SDS-PAGE. 
The protein concentration was measured with BCA protein assay (Thermo Scientific). 
Recombinant purified pUL5 was injected in a group of 4 mice with 3 doses, once per 14 days, 
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of 20 μg of recombinant protein formulated in Freund adjuvant. At the end of the protocol the 
mice were sacrificed and sera collected. 
Confocal microscopy analysis. HFF cells grown on glass cover slips in 24-well plates 
were infected at MOI 5. At different time points after infection, the cover slips were washed 
and fixed in Cytofix/Cytoperm™ buffer (BD Biosciences). The fixed cells were incubated in 
blocking buffer (phosphate-buffered saline - PBS + 5% non-immune human serum) for 30 
minutes before antibody staining. Primary and secondary antibodies were always diluted in 
blocking buffer and incubated for 30 min at room temperature. Coverslips were mounted using 
ProLong
®
 Gold Antifade Mountant with DAPI (Life Technologies). The intracellular staining 
was examined under laser illumination in a Zeiss LMS 710 confocal microscope and images 
were captured using ZEN software (Carl Zeiss). Images were processed using ImageJ software. 
SDS-PAGE and immunoblotting. Proteins were separated by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on 4-12% polyacrylamide pre-cast gels (Life 
Technologies) under standard conditions. Proteins were transferred to nitrocellulose 
membranes (iBlot
®
 system – Life Technologies), and membranes were blocked with PBS 
containing 0.05% Tween 20 and 10% powdered milk. Antibodies and sera were diluted in 
PBS containing 0.05% Tween 20 and 1% powdered milk. For detection of primary antibody 
binding, horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG antibody and the 
West Pico Chemoluminescent Substrate (Thermo Scientific) were used according to the 
manufacturer’s instructions. Removal of N-linked oligosaccharides was carried out using 
recombinant peptide:N-glycosidase F (PNGase F) and endoglycosidase H (Endo H) (NEB) 
according to the manufacturer’s specification. 
HCMV Virions purification and virion protein fractionation. Mature HCMV 
virions were separated from non-infectious enveloped particles (NIEPs) and dense bodies (DB) 
through a positive density/negative viscosity step-gradient centrifugation as described 
previously [35]. Briefly, supernatant of infected cells was collected when 100% of cytopathic 
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effect was observed and subjected to 4000 rpm centrifugation for 20 minutes at 4°C. Clear 
supernatant was transferred to polycarbonate ultracentrifuge tubes under lied with 20% 
sucrose cushion and centrifuged at 23000 rpm in a Beckman SW32Ti rotor for 60 minutes. 
The pelleted virus was resuspended in 1 ml PBS, 2.5 ml of 4 different solutions containing 
decreasing concentration of sucrose and increasing concentration of glycerol tartrate were 
layered underneath. Tubes were centrifuged at 42000 rpm for 60 min at 10°C in a Beckman 
SW28Ti rotor. Bands containing mature virions were collected through a syringe 25 gauge, 
resuspended in PBS and centrifuged at 23000 rpm in a Beckman SW32Ti rotor for 60 min. 
The virus-containing pellet was resuspended in PBS. To separate envelope from capsid and 
tegument proteins, purified virions were mixed 1:1 with envelope extraction buffer (1% 
Nonidet-P (NP)-40 and 4% Sodium Deoxycholate) and incubated on ice for 30 min with 
occasional vortexing. Soluble fraction (envelope) was collected through centrifugation at 
13000 rpm in a benchtop centrifuge for 30 min at 4°C. The insoluble pellet (capsid and 
tegument) was washed twice with PBS before being solubilized in SDS-PAGE sample buffer. 
For each extraction, a total of 4 confluent T175 cm
2
 flasks of HFF cells were infected. 
Viral replication kinetics and titration. To assay the replication kinetics of the viral 
mutants, one day after seeding 1.25x10
5
 HFF cells per well in 12-well plates, cells were 
infected in quadruplicates with 500μl of different dilutions of infectious supernatant at 37°C 
for 3 h. After incubation, the infectious inoculum was removed and fresh medium was added. 
The next day, one of the four cultures of each dilution was assayed to determine the 
percentage of infection via immediate early antigen 1 immuno-staining. The dilutions resulting 
in approximately 60% of infected cells were chosen to assay the viral replication kinetics. To 
this end, supernatant from the three remaining cultures was taken at different time points after 
infection and stored at room temperature until titration. To determine the virus titer, 3x10
5
 
HFF cells per well were seeded in a 96-well plate the day before the experiment. Virus stocks 
were serially diluted l0fold and 50 µl of diluted virus was seeded in triplicate wells. After a 3 h 
incubation at 37°C, the virus containing medium was removed and replaced with fresh 
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medium. After 16 h incubation the medium was removed and the plate washed trice with 
Dulbecco’s phosphate buffered saline (DPBS, pH 7.4) and fixed in absolute ethanol for 15 min 
at room temperature. Following removal of the ethanol, the plate was rehydrated with DPBS 
for 20 min at room temperature. The wells were then incubated with 0.1-0.3 µg per well of 
mouse anti-IE1 diluted in DPBS for 1 h at 37°C. After washing the wells five times with 
DPBS, 0.1 ml of FITC-conjugated goat anti-mouse IgG diluted l/100 in DPBS was added and 
the plate incubated for 1 h at 37°C. The wells were then washed twice with DPBS and 50µl of 
DPBS containing 30% glycerol was added. The plate was viewed with Zeiss Axiovert 200 
fluorescence microscope with a stage adapter for reading multiwell plates. Fluorescent nuclei 
were counted and infectivity expressed as infectious units IU (fluorescent nuclei) per ml of 
inoculum. 
Pull-down coupled with mass spectrometry and immunoprecipitations. For pull-
down experiments HFF cells were infected with the recombinant or wild-type viruses at MOI 
3. Cell lysates were prepared with CelLytic M (Sigma-Aldrich) according to manufacturer’s 
specifications. Pull-down was carried out using anti-FLAG
®
 M2 magnetic beads (Sigma-
Aldrich) according to manufacturer’s instructions; the binding step was prolonged overnight 
and protein complexes were eluted by competition with the FLAG peptide. Eluted fractions 
were subjected to SDS-PAGE and stained with colloidal Coomassie G-250. Bands of interest 
were cut, dehydrated with acetonitrile for 15 minutes and digested with trypsin overnight at 
37°C, then spotted on the target 1:1 with recrystallization buffer (70% ethanol, 1% 
trifluoroacetic acid) and analyzed by MALDI-TOF. The trypsin spectrum was subtracted from 
the resulting spectra and the final peaks were searched on Mascot database (MatrixScience). 
For immunoprecipitations (IP), HEK-293T cells were transfected with Lipofectamine 2000 
(Life Technologies) and lysates were prepared using CelLytic M (Sigma-Aldrich). IPs were 
carried out using Dynabeads
®
 Protein G (Life Technologies) according to manufacturer’s 
specifications, using 5 µg of antibody for IP reaction. 
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Sequence analysis. The amino-acid sequences for the UL5 coding sequences from 
laboratory adapted HCMV  strains and clinical isolates have been assigned the following 
accession numbers from GenBank: AGL96607.1, AAS48922.1, AFR56339.1, AFR56172.1, 
AFR56005.1, AFR54510.1, AGT36439.1, ACZ80259.1, ACZ80094.1, ACZ79929.1, 
ACZ79764.1, ACS92108.1, ACM47996.1, ACL51086.1, AAR31292.1 and AAR31275.1. 
Multiple alignment was performed using CLUSTALW [14]; N-, and O-glycosylation sites, 
signal peptides and transmembrane regions were predicted using NetNGlyc [17], NetOGlyc 
[18], SignalP [16] and PSORTII [15] servers, respectively. 
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